5QTW
 
 | | FACTOR XIA IN COMPLEX WITH THE INHIBITOR methyl (2R,7S)-7-({(2E)-3-[5-chloro-2-(1H-tetrazol-1-yl)phenyl]prop-2-enoyl}amino)-14-[(methoxycarbonyl)amino]-2,3,4,5,6,7-hexahydro-1H-8,11-epimino-1,9-benzodiazacyclotridecine-2-carboxylate | | Descriptor: | 1,2-ETHANEDIOL, Coagulation factor XI, SULFATE ION, ... | | Authors: | Sheriff, S. | | Deposit date: | 2019-11-13 | | Release date: | 2020-01-29 | | Last modified: | 2024-10-23 | | Method: | X-RAY DIFFRACTION (2.12 Å) | | Cite: | Orally bioavailable amine-linked macrocyclic inhibitors of factor XIa.
Bioorg.Med.Chem.Lett., 30, 2020
|
|
5QTV
 | | FACTOR XIA IN COMPLEX WITH THE INHIBITOR methyl [(2R,7S)-7-({(2E)-3-[5-chloro-2-(1H-tetrazol-1-yl)phenyl]prop-2-enoyl}amino)-2-(trifluoromethyl)-2,3,4,5,6,7-hexahydro-1H-8,11-epimino-1,9-benzodiazacyclotridecin-14-yl]carbamate | | Descriptor: | 1,2-ETHANEDIOL, Coagulation factor XI, SULFATE ION, ... | | Authors: | Sheriff, S. | | Deposit date: | 2019-11-13 | | Release date: | 2020-01-29 | | Last modified: | 2024-10-23 | | Method: | X-RAY DIFFRACTION (2.2 Å) | | Cite: | Orally bioavailable amine-linked macrocyclic inhibitors of factor XIa.
Bioorg.Med.Chem.Lett., 30, 2020
|
|
5QTX
 | | FACTOR XIA IN COMPLEX WITH THE INHIBITOR ethyl (2R,7S)-7-({(2E)-3-[5-chloro-2-(1H-tetrazol-1-yl)phenyl]prop-2-enoyl}amino)-14-[(methoxycarbonyl)amino]-1,2,3,4,5,6,7,9-octahydro-11,8-(azeno)-1,9-benzodiazacyclotridecine-2-carboxylate | | Descriptor: | 1,2-ETHANEDIOL, Coagulation factor XI, SULFATE ION, ... | | Authors: | Sheriff, S. | | Deposit date: | 2019-11-13 | | Release date: | 2020-01-29 | | Last modified: | 2024-10-23 | | Method: | X-RAY DIFFRACTION (2.07 Å) | | Cite: | Orally bioavailable amine-linked macrocyclic inhibitors of factor XIa.
Bioorg.Med.Chem.Lett., 30, 2020
|
|
5QTY
 | | FACTOR XIA IN COMPLEX WITH THE INHIBITOR ethyl (2R,7S)-7-({(2E)-3-[5-chloro-2-(1H-tetrazol-1-yl)phenyl]prop-2-enoyl}amino)-15-[(methoxycarbonyl)amino]-2,3,4,5,6,7-hexahydro-1H-12,8-(metheno)-1,9-benzodiazacyclotetradecine-2-carboxylate | | Descriptor: | 1,2-ETHANEDIOL, Coagulation factor XI, SULFATE ION, ... | | Authors: | Sheriff, S. | | Deposit date: | 2019-11-13 | | Release date: | 2020-01-29 | | Last modified: | 2024-10-16 | | Method: | X-RAY DIFFRACTION (1.89 Å) | | Cite: | Orally bioavailable amine-linked macrocyclic inhibitors of factor XIa.
Bioorg.Med.Chem.Lett., 30, 2020
|
|
6NZF
 | |
6NZE
 | |
6NZH
 | |
6NZR
 | |
6NZP
 | |
6NZQ
 | |
7UZN
 | | CRYSTAL STRUCTURE OF THE FIRST BROMODOMAIN OF HUMAN BRD4 IN COMPLEX WITH BMT-206059 AKA 2-{(3M)-3-(1,4-DIMETHYL-1H-1,2,3-TRIAZOL-5-YL)-8-FLUORO-5-[(S)-(OXAN-4-YL)(PHENYL)METHYL]-5H-PYRIDO[3,2-b]INDOL-7-YL}PROPAN-2-OL, TRIPLY DEUTERATED ON THE 4-METHYL GROUP | | Descriptor: | 1,2-ETHANEDIOL, 2-{(3M)-3-(1,4-dimethyl-1H-1,2,3-triazol-5-yl)-8-fluoro-5-[(S)-(oxan-4-yl)(phenyl)methyl]-5H-pyrido[3,2-b]indol-7-yl}propan-2-ol, Bromodomain-containing protein 4, ... | | Authors: | Sheriff, S. | | Deposit date: | 2022-05-09 | | Release date: | 2022-08-17 | | Last modified: | 2023-10-18 | | Method: | X-RAY DIFFRACTION (1.685 Å) | | Cite: | Development of BET Inhibitors as Potential Treatments for Cancer: Optimization of Pharmacokinetic Properties.
Acs Med.Chem.Lett., 13, 2022
|
|
3ENS
 | |
2H5E
 | | Crystal structure of E.coli polypeptide release factor RF3 | | Descriptor: | GUANOSINE-5'-DIPHOSPHATE, Peptide chain release factor RF-3 | | Authors: | Song, H.W, Zhou, Z.H. | | Deposit date: | 2006-05-26 | | Release date: | 2007-05-15 | | Last modified: | 2024-03-13 | | Method: | X-RAY DIFFRACTION (2.8 Å) | | Cite: | RF3 induces ribosomal conformational changes responsible for dissociation of class I release factors
Cell(Cambridge,Mass.), 129, 2007
|
|
7MCF
 | | CRYSTAL STRUCTURE OF THE FIRST BROMODOMAIN OF HUMAN BRD4 IN COMPLEX WITH 2-{3-(1,4-dimethyl-1H-1,2,3-triazol-5-yl)-6-fluoro-5-[(S)-(3-fluoropyridin-2-yl)(oxan-4-yl)methyl]-5H-pyrido[3,2-b]indol-7-yl}propan-2-ol | | Descriptor: | 2-{3-(1,4-dimethyl-1H-1,2,3-triazol-5-yl)-6-fluoro-5-[(S)-(3-fluoropyridin-2-yl)(oxan-4-yl)methyl]-5H-pyrido[3,2-b]indol-7-yl}propan-2-ol, Bromodomain-containing protein 4 | | Authors: | Sheriff, S. | | Deposit date: | 2021-04-02 | | Release date: | 2021-05-26 | | Last modified: | 2023-10-18 | | Method: | X-RAY DIFFRACTION (2.19 Å) | | Cite: | Development of BET inhibitors as potential treatments for cancer: A search for structural diversity.
Bioorg.Med.Chem.Lett., 44, 2021
|
|
8IIU
 | | anti-VEGF nanobody | | Descriptor: | SULFATE ION, anti-VEGF nanobody | | Authors: | Qian, F, Zhu, S.Q. | | Deposit date: | 2023-02-24 | | Release date: | 2023-12-27 | | Last modified: | 2024-10-23 | | Method: | X-RAY DIFFRACTION (1.27 Å) | | Cite: | Polymorphic nanobody crystals as long-acting intravitreal therapy for wet age-related macular degeneration.
Bioeng Transl Med, 8, 2023
|
|
8IJZ
 | | anti-VEGF mutant | | Descriptor: | anti-VEGF nanobody | | Authors: | Qian, F, Zhu, S.Q. | | Deposit date: | 2023-02-28 | | Release date: | 2023-12-27 | | Last modified: | 2024-10-09 | | Method: | ELECTRON CRYSTALLOGRAPHY (2.1 Å) | | Cite: | Polymorphic nanobody crystals as long-acting intravitreal therapy for wet age-related macular degeneration.
Bioeng Transl Med, 8, 2023
|
|
8IJS
 | | anti-VEGF nanobody mutant | | Descriptor: | ZINC ION, anti-VEGF nanobody | | Authors: | Qian, F, Zhu, S.Q. | | Deposit date: | 2023-02-28 | | Release date: | 2023-12-27 | | Last modified: | 2024-10-09 | | Method: | X-RAY DIFFRACTION (1.752 Å) | | Cite: | Polymorphic nanobody crystals as long-acting intravitreal therapy for wet age-related macular degeneration.
Bioeng Transl Med, 8, 2023
|
|
8DY2
 | | Crystal Structure of spFv GLK1 | | Descriptor: | SULFATE ION, spFv GLK1 LH | | Authors: | Luo, J, Boucher, L.E. | | Deposit date: | 2022-08-03 | | Release date: | 2023-05-03 | | Last modified: | 2024-10-16 | | Method: | X-RAY DIFFRACTION (1.65 Å) | | Cite: | "Stapling" scFv for multispecific biotherapeutics of superior properties.
Mabs, 15, 2023
|
|
8DY4
 | | Crystal Structure of spFv CAT2200 HL | | Descriptor: | spFv CAT2200 HL | | Authors: | Luo, J, Boucher, L.E. | | Deposit date: | 2022-08-03 | | Release date: | 2023-05-03 | | Last modified: | 2024-11-20 | | Method: | X-RAY DIFFRACTION (2.4 Å) | | Cite: | "Stapling" scFv for multispecific biotherapeutics of superior properties.
Mabs, 15, 2023
|
|
8DY0
 | | Crystal Structure of spFv GLK1 HL | | Descriptor: | spFv GLK1 HL | | Authors: | Luo, J, Boucher, L.E. | | Deposit date: | 2022-08-03 | | Release date: | 2023-05-03 | | Last modified: | 2024-11-13 | | Method: | X-RAY DIFFRACTION (2.1 Å) | | Cite: | "Stapling" scFv for multispecific biotherapeutics of superior properties.
Mabs, 15, 2023
|
|
8DY5
 | |
8DY1
 | |
8DY3
 | | Crystal Structure of spFv GLK2 HL | | Descriptor: | SULFATE ION, spFv GLK2 HL | | Authors: | Luo, J, Boucher, L.E. | | Deposit date: | 2022-08-03 | | Release date: | 2023-05-03 | | Last modified: | 2024-10-23 | | Method: | X-RAY DIFFRACTION (1.509 Å) | | Cite: | "Stapling" scFv for multispecific biotherapeutics of superior properties.
Mabs, 15, 2023
|
|
4FRS
 | |
7MP5
 | | Autoinhibited neurofibrobmin | | Descriptor: | Isoform I of Neurofibromin | | Authors: | Lupton, C.J, Bayly-Jones, C, Ellisdon, A.M. | | Deposit date: | 2021-05-04 | | Release date: | 2021-12-15 | | Last modified: | 2024-05-29 | | Method: | ELECTRON MICROSCOPY (5.6 Å) | | Cite: | The cryo-EM structure of the human neurofibromin dimer reveals the molecular basis for neurofibromatosis type 1.
Nat.Struct.Mol.Biol., 28, 2021
|
|
